Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc. reported a substantial revenue increase of 76% year-over-year in Q3 FY25, primarily driven by the successful integration of the SCN model, which has led to accelerated adoption and case starts with minimal additional investment. The company experienced significant growth in service revenue, which more than doubled to $4.6 million, highlighting the effectiveness of its sleep testing and treatment-center services. With ongoing deployment of specialized operating teams and a strong market presence, particularly in North America and the rapidly expanding Asia Pacific region, Vivos Therapeutics is well-positioned for continued revenue growth as awareness of sleep disorders increases.

Vivos Therapeutics Inc. has experienced a year-over-year revenue decline of 9% in the first half of 2025, primarily due to the transition to a new direct sleep center management model, which has led to ongoing operational challenges. Additionally, gross margins have dropped to 55% as a result of discounting practices and a change in product and service mix, indicating pressure on profitability. The company also faces significant risks, including lower-than-expected sales growth, difficulty in securing capital for expansion, and a history of operating losses and negative cash flow, raising concerns about its ability to achieve sustainable profitability.